Experimental blood cancer drug KK2430 enters first human tests
NCT ID NCT07629726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time the experimental drug KK2430 is being tested in humans. It aims to find out if KK2430 is safe, how the body processes it, and whether it can help treat blood cancers. About 72 adults with blood cancers that have not responded to other treatments will receive the drug intravenously. The study is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KK2430 (an experimental drug given intravenously)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with blood cancers.
What could go wrong
This is a very early, first-in-human study with only 72 participants. The drug may not work or could have serious side effects. It will take years before any potential treatment is available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prisma Health
RECRUITINGGreenville, South Carolina, 29605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••